Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.41 -7.35%
Revenue Growth %: +5.9%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +5.9%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- TETRA Technologies (TTI) Tops Q3 EPS by 1c, Beats on Revenue
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
